User talk:173.226.187.82

Ocaratuzumab is a humanized, next-generation anti-CD20 monoclonal antibody currently in development by Mentrik Biotech, LLC for relapsed follicular lymphoma and other hematologic malignancies. The antibody is engineered for enhanced affinity to CD20, increased antibody-dependent cell-mediated cytotoxicity (ADCC), and for improved treatment of low-affinity FcγRIIIa allotypes.

Phase I/II trials in relapsed follicular lymphoma have been completed in the United States (US) and Japan, and a Phase I trial was conducted in US rheumatoid arthritis patients. Phase III development in relapsed follicular lymphoma patients is underway. Many patients relapse following currently available treatments, and a significant need for new effective treatment exists, particularly for patients with low-affinity FcγRIIIa allotypes. In pre-clinical studies, ocaratuzumab was shown to have 13 to 20 fold greater affinity for CD20 and 6 fold more potent ADCC as compared to rituximab. Additional development in other oncology and rheumatology indications will also be pursued, as well as subcutaneous formations for patient convenience.

Mentrik Biotech, LLC is a private biopharmaceutical company headquartered in Dallas, TX. The goal of Mentrik Biotech is to optimize oncology-based therapeutics to treat patients with significant unmet medical needs. The company aims to develop convenient, potent, and cost-effective anti-cancer molecules to enhance treatment options for patients and fulfill unmet therapeutic needs. For more information, visit www.mentrik.com.

Your submission at Articles for creation


I noticed your submission in Articles for creation, Wikipedia talk:Articles for creation/Ocaratuzumab (AME-133v). Thanks! It will be reviewed by a volunteer soon.

Before it can be added to Wikipedia, your submission should have references. All articles on Wikipedia should have inline, numbered references after facts, showing the 'reliable source' (a newspaper, book, etc.) where the information can be checked, so that all information is verifiable.

Here's an example of how to add references: Chzz is 98 years old.&lt;ref> "The book of Chzz", Aardvark Books, 2009. &lt;/ref>

He likes tea.&lt;ref> Smith, John. " Interview with Chzz", Foo News, 1 April 2010. Retrieved 2011-05-22.

== References ==

That makes the references automatically display as small numbers[1] which will link to the details in the section titled == References == at the end. You can see that example in action here.

Please add references to your submission, which will be reviewed as soon as possible. See also, Referencing for beginners. If you need any help, just put at the end of this page, followed by a question or get into our live help chat chanel at.

Best, ChzzBot IV (talk) 00:04, 4 February 2012 (UTC)

Wikipedia talk:Articles for creation/Ocaratuzumab (AME-133v) concern
Hi there, I'm HasteurBot. I just wanted to let you know that Wikipedia talk:Articles for creation/Ocaratuzumab (AME-133v), a page you created has not been edited in at least 180 days. The Articles for Creation space is not an indefinite storage location for content that is not appropriate for articlespace. If your submission is not edited soon, it could be nominated for deletion. If you would like to attempt to save it, you will need to improve it. If the deletion has already occured, instructions on how you may be able to retrieve it are available at WP:REFUND/G13. Thank you for your attention. HasteurBot (talk) 00:03, 17 August 2013 (UTC)

Your article submission Ocaratuzumab (AME-133v)


Hello 173.226.187.82. It has been over six months since you last edited your article submission, entitled Ocaratuzumab (AME-133v).

The page will shortly be deleted. If you plan on editing the page to address the issues raised when it was declined and resubmit it, simply and remove the  or  code. Please note that Articles for Creation is not for indefinite hosting of material deemed unsuitable for the encyclopedia mainspace.

If your submission has already been deleted by the time you get there, and you want to retrieve it, copy this code:, paste it in the edit box at this link , click "Save", and an administrator will in most cases undelete the submission.

Thanks for your submission to Wikipedia, and happy editing. HasteurBot (talk) 15:07, 3 November 2013 (UTC)